INO
Closed
Inovio Pharmaceuticals Inc
2.04
+0.01 (+0.49%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.035
Day's Range: 1.93 - 2.145
Send
sign up or login to leave a comment!
When Written:
0.7866
Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development of DNA-based immunotherapies and vaccines. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio's technology platform is based on synthetic DNA that is designed to activate an immune response against specific pathogens or cancer cells. The company's lead product candidate, VGX-3100, is a DNA-based immunotherapy for the treatment of cervical dysplasia caused by human papillomavirus (HPV).
In addition to VGX-3100, Inovio has a pipeline of other product candidates in various stages of development for the treatment of infectious diseases, cancer, and autoimmune disorders. The company has partnerships with various organizations, including the Bill and Melinda Gates Foundation and the National Institutes of Health.
Inovio has faced some controversy and skepticism over its technology and clinical trial results, but the company has continued to pursue its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Inovio's technology platform is based on synthetic DNA that is designed to activate an immune response against specific pathogens or cancer cells. The company's lead product candidate, VGX-3100, is a DNA-based immunotherapy for the treatment of cervical dysplasia caused by human papillomavirus (HPV).
In addition to VGX-3100, Inovio has a pipeline of other product candidates in various stages of development for the treatment of infectious diseases, cancer, and autoimmune disorders. The company has partnerships with various organizations, including the Bill and Melinda Gates Foundation and the National Institutes of Health.
Inovio has faced some controversy and skepticism over its technology and clinical trial results, but the company has continued to pursue its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








